Epidermal growth factor receptor 2 (HER2) inhibitors, including pertuzumab, trastuzumab, trastuzumab-emtansine, trastuzumab deruxtecan, lapatinib, tucatinib, and neratinib are used for treating HER2-positive breast cancer [10], whilst inhibitors of BRAF (dabrafenib, vemurafenib) are given together with MEK inhibitors (trametinib, cometinib) in BRAF-mutated melanoma [9]. The gene discussed is BRAF; the disease is melanoma.